BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors
POMPANO BEACH, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed Mr. Patrick Daly to its Board of Directors.
Related news for (BSEM)
- BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
- BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
- BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
- BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
- BioStem Technologies to Sponsor MRO Better Half Dash